Market Pulse Archives

Aug. 17, 2021, 3:03 p.m. EDT

Roche says arthritis drug authorized to treat hospitalized COVID-19 patients is in short supply

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Roche Holding AG (ROG)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Roche Holding AG /zigman2/quotes/206324342/delayed CH:ROG -0.72% said Monday that Actemra, its rheumatoid arthritis drug that recently received authorization in the U.S. as a COVID-19 treatment for hospitalized patients, is in short supply and will be so for weeks or months. The drug "has been widely used to treat hospitalized patients with severe or critical COVID-19 around the world, and demand for this medicine has increased to unprecedented levels globally," the company said. Demand for Actemra in the U.S., where the delta variant is behind the recent surge in cases and hospitalizations, is "well beyond 400% of pre-COVID levels over the last two weeks alone," according to Roche, which cited manufacturing limits, supply constraints, and the labor-intensive process of developing biologic drugs as reasons for the shortage. Roche's stock is up 15.6% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +1.99% has gained 19.2%.

CH : Switzerland: SWX
CHF 330.60
-2.40 -0.72%
Volume: 541,645
May 27, 2022 3:05p
P/E Ratio
Dividend Yield
Market Cap
CHF271.31 billion
Rev. per Employee
+79.11 +1.99%
Volume: 2.40B
May 26, 2022 5:42p

Get news alerts on S&P 500 Index — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.